LENSAR (NASDAQ:LNSR – Get Free Report) and Sanara MedTech (NASDAQ:SMTI – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk and valuation.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for LENSAR and Sanara MedTech, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LENSAR | 1 | 0 | 2 | 0 | 2.33 |
| Sanara MedTech | 1 | 4 | 0 | 0 | 1.80 |
LENSAR presently has a consensus price target of $11.00, indicating a potential upside of 107.94%. Sanara MedTech has a consensus price target of $35.00, indicating a potential upside of 6.84%. Given LENSAR’s stronger consensus rating and higher probable upside, research analysts clearly believe LENSAR is more favorable than Sanara MedTech.
Insider and Institutional Ownership
40.1% of LENSAR shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 65.8% of LENSAR shares are held by company insiders. Comparatively, 42.0% of Sanara MedTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares LENSAR and Sanara MedTech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| LENSAR | 56.07% | 1,254.25% | 49.13% |
| Sanara MedTech | -2.69% | 32.45% | 3.21% |
Earnings and Valuation
This table compares LENSAR and Sanara MedTech”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| LENSAR | $58.44 million | 1.11 | -$34.28 million | ($0.40) | -13.22 |
| Sanara MedTech | $103.12 million | 2.92 | -$37.56 million | ($0.35) | -93.60 |
LENSAR has higher earnings, but lower revenue than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than LENSAR, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
LENSAR has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500.
Summary
LENSAR beats Sanara MedTech on 10 of the 14 factors compared between the two stocks.
About LENSAR
LENSAR, Inc. develops and markets laser-based technology for ophthalmic surgery, with a focus on procedures used to treat cataracts. Its systems are designed to assist surgeons with key steps in cataract surgery, including the creation of incisions and the fragmentation of the eye’s natural lens. The company’s products include the ALLY Adaptive Cataract Treatment System and the LENSAR Laser System, which use imaging and software to support surgical planning and treatment. LENSAR also offers related software, accessories and services for ophthalmic practices and surgical facilities.
About Sanara MedTech
Sanara MedTech, Inc. develops, markets and distributes medical products for wound care, surgical tissue repair and related applications. Its offerings are intended for use by healthcare professionals treating acute and chronic wounds and supporting tissue healing. The company’s portfolio includes CellerateRX® collagen-based products and BIAKŌS® antimicrobial products, along with other solutions for wound and surgical care. Sanara sells its products to healthcare providers and through distribution channels.
Receive News & Ratings for LENSAR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENSAR and related companies with MarketBeat.com's FREE daily email newsletter.
